Shares of Shire PLC (NASDAQ:SHPG) have earned a consensus recommendation of “Buy” from the twenty-seven brokerages that are currently covering the stock. Four analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $224.86.

Several research firms recently issued reports on SHPG. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a research report on Thursday, November 3rd. HSBC lowered Shire PLC from a “buy” rating to a “hold” rating in a research report on Monday, September 26th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Shire PLC in a research report on Monday, October 3rd. Zacks Investment Research upgraded Shire PLC from a “hold” rating to a “buy” rating and set a $211.00 price objective on the stock in a research report on Friday, October 21st. Finally, Piper Jaffray Cos. set a $201.00 price objective on Shire PLC and gave the stock a “hold” rating in a research report on Saturday, October 1st.

Several hedge funds have recently modified their holdings of SHPG. Jennison Associates LLC raised its stake in shares of Shire PLC by 13.2% in the second quarter. Jennison Associates LLC now owns 8,294,030 shares of the biopharmaceutical company’s stock valued at $1,526,765,000 after buying an additional 968,101 shares during the last quarter. FMR LLC raised its stake in shares of Shire PLC by 86.7% in the second quarter. FMR LLC now owns 2,663,506 shares of the biopharmaceutical company’s stock valued at $490,297,000 after buying an additional 1,237,100 shares during the last quarter. Lone Pine Capital LLC purchased a new stake in shares of Shire PLC during the second quarter valued at approximately $465,566,000. Capital World Investors purchased a new stake in shares of Shire PLC during the second quarter valued at approximately $285,568,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Shire PLC during the second quarter valued at approximately $278,421,000. 24.22% of the stock is owned by institutional investors.

Shares of Shire PLC (NASDAQ:SHPG) opened at 189.84 on Tuesday. Shire PLC has a one year low of $147.60 and a one year high of $219.52. The company’s 50-day moving average price is $0.00 and its 200 day moving average price is $0.00.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $3.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.21 by $0.04. Shire PLC had a return on equity of 14.81% and a net margin of 1.62%. The company had revenue of $3.45 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the previous year, the business earned $3.24 earnings per share. Shire PLC’s revenue was up 108.6% compared to the same quarter last year. On average, analysts expect that Shire PLC will post $12.94 earnings per share for the current fiscal year.

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

5 Day Chart for NASDAQ:SHPG

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.